Clinical Trial

Evidence for Potassium Restriction in Hemodialysis

Study acronym: EvoKe-HD
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 16, 2025 (before its estimated March 12, 2026 completion). Its status may not reflect the trial's current state.
Summary
EvoKe-HD is a pilot randomized controlled trial to assess the feasibility and potential for efficacy of a novel dietary approach to hyperkalemia. Contrary to the traditional recommendations limiting the intake of high-potassium whole foods, such as fruits and vegetables, the investigators propose to switch the focus to foods containing potassium that is readily absorbed by the body (high bioavailability), such as potassium from additives, processed meats, milk, fruit juices and sugary drinks.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-11-04; most recent amendment 2025-12-08.
Status change: Recruiting → Active, Not Recruiting 2025-12-08
Status change: Not Yet Recruiting → Recruiting 2025-11-19
Trial Details
NCT Number NCT06120608
Lead Sponsor Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Collaborators: Canadian Institutes of Health Research (CIHR)
Conditions Hyperkalemia, Diminished Renal Excretion
Enrollment 50 participants
Start Date 2025-06-17
Primary Completion 2026-03-12 (estimated)
Study Completion 2026-03-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-16